Future horizons for CAR T-cells, bispecifics and other advanced therapy medicinal products in multiple myeloma

EHA Library, Hermann Einsele, 312348

What I need to know about advanced therapy medicinal products for my clinical practice – facts or fiction: An interactive d

EHA Library, Joseph Mikhael, 312346

Panel Discussion and Q&A

EHA Library, Faculty / Presenters, 312347

Follicular lymphoma from genetics to the clinic

EHA Library, Gilles Salles, 313417

Session Opening & Zooming in on T-cell engaging therapies in NHL

EHA Library, S Dietrich, 312345

Focus on bispecific antibody safety: are there any new signals?

EHA Library, Martin Hutchings, 312342

Panel Discussion & Closing

EHA Library, Faculty / Presenters, 312341

Recommendations and consensus for the use of IgG therapy in patients with hematological malignancies and secondary immune d

EHA Library, M Albert, 312340

Summary and close

EHA Library, Ifeyinwa Osunkwo, 312336

Living with SCD: Understanding the consequences

EHA Library, R Colombatti, 312334

Effective management of VOCs: Overcoming barriers and finding solutions

EHA Library, Ifeyinwa Osunkwo, 312333

Asparaginase pharmacokinetics and pharmacodynamics

EHA Library, M Relling, 312328

Questions and Discussion

EHA Library, Nicola GÖKBUGET, 312326

What impact will CD20/CD3 bispecific antibodies have on the evolving NHL treatment landscape?

EHA Library, Franck Morschhauser, 312344

Understanding the latest clinical data for bispecific antibodies and other T-cell engaging therapies in NHL

EHA Library, Sarit Assouline, 312343

Future perspectives and closing remarks

EHA Library, Tadeusz Robak, 312339

Session Opening & The burden of infection in Chronic Lymphocytic Leukemia and Multiple Myeloma/COVID-19 in patients with ch

EHA Library, Tadeusz Robak, 312338

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

EHA Library, Marion Subklewe, 312337

Impact and treatment of SCD: Hearing the patient viewpoint

EHA Library, John James, 312335

Welcome and Introduction

EHA Library, Ifeyinwa Osunkwo, 312332

COVID-19 and SCD: The experts in conversation

EHA Library, Ifeyinwa Osunkwo, 312331

Toxicities in adult versus pediatric ALL patients and consequences for management

EHA Library, K Schmiegelow, 312330

Efficacy, tolerability and management strategies in the GMALL trials

EHA Library, Nicola GÖKBUGET, 312329

Q&A

EHA Library, Faculty / Presenters, 312327

Q&A

EHA Library, Faculty / Presenters, 312325

Sickle cell disease as a chronic problem

EHA Library, Marianne de Montalambert, 313485

Niche contributions to bone marrow failure and clonal evolution in MDS

EHA Library, Marc Raaijmakers, 313482

Potentially druggable targets in transformed disease

EHA Library, Davide Rossi, 313478

Current treatment options for transformed disease

EHA Library, Silvia Montoto, 313477

Biological basis of transformation

EHA Library, Ulf Klein, 313476

TTP vs HUS - Novel insights

EHA Library, Marie Scully, 313475

Immune thrombocytopenia (ITP): New insights on pathophysiology

EHA Library, John Semple, 313474

Inherited platelet disorders and mutations in hematopoietic transcription factors

EHA Library, A. Koneti Rao, 313473

Eosinophilia

EHA Library, Andreas Reiter, 313466

Management of MM patients with high-risk disease

EHA Library, Jesús San Miguel, 313457

Testicular lymphoma

EHA Library, Annalisa Chiappella, 313453

Management of post allogeneic HCT auto/alloimmune cytopenia

EHA Library, Andreas Holbro, 313436

Drug induced immune hemolytic disease: Diagnostic challenges

EHA Library, Quentin A Hill, 313435

Novel treatment options

EHA Library, Subarna Chakravorty, 313426

Epidemiology of Hbpathies in Europe

EHA Library, Fred Piel, 313429

Vulnerabilities of indolent lymphomas: The tumor and the microenvironment

EHA Library, Leticia Quintanilla de Fend, 313437

Building blocks to optimize CLL treatment

EHA Library, Thorsten Zenz, 313440

Genetic heterogeneity of congenital neutropenias

EHA Library, Karl Welte, 313444

New drugs and BMT: How to choose

EHA Library, Maria Domenica Cappellini, 313450

Primary mediastinal lymphoma

EHA Library, Maurizio Martelli, 313452

Immunotherapy and other novel immunological therapies

EHA Library, Daniel Olive, 313458

Natural Killer Cell-Mediated Immunosurveillance of leukemia

EHA Library, Yenan Bryceson, 313459

Basis of iron regulation for erythropoiesis

EHA Library, Laura SILVESTRI, 313461

Classification and clinical approach to atypical microcytic anemias

EHA Library, Patricia Aguilar Martinez, 313462

Treatment of the older patient with AML

EHA Library, Courtney DiNardo, 313469

New insights in the pathogenesis of autoimmune hemolytic diseases

EHA Library, Wilma Barcellini, 313434

The molecular basis of p53 mutations in MDS

EHA Library, Benjamin Ebert, 313483

Novel agents for phase 3 trials

EHA Library, Michel Zwaan, 313433

Advances in risk stratification in pediatric acute lymphoblastic leukemia

EHA Library, Anthony Moorman, 313432

ALL subtypes

EHA Library, Ilaria Iacobucci, 313431

Red cell transfusions: Current best practice and how to further optimize?

EHA Library, Marlijn Hoeks, 313430

Real life CAR T treatment

EHA Library, Catherine Thieblemont, 313427

Iron overload, monitoring and management

EHA Library, Ali Taher, 313425

CAR T cells

EHA Library, Paula Rodríguez-Otero, 313424

T-cell engaging antibodies for hematological diseases from approved therapies to new indications

EHA Library, Hermann Einsele, 313423

Improving efficacy and persistence of CAR-T cell

EHA Library, Christian Chabannon, 313422

Hydroxyurea: Fertility a still open question in adulthood

EHA Library, David Rees, 313421

Update on oral contraception and VTE

EHA Library, Marc Blondon, 313480

METFORMIN AND STATINS DO NOT LOWER MYELOFIBROSIS INCIDENS, OVERALL SURVIVAL OR RISK OF LEUKEMIC TRANFORMATION: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Daniel Kristensen, 293583

SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 293586

A PHASE 2 STUDY OF BOMEDEMSTAT (IMG-7289), A LYSINE-SPECIFIC DEMETHYLASE-! (LSD!) INHIBITOR, FOR THE TREATMENT OF LATER-STAGE MYELOFIBROSIS (MF)

EHA Library, Kristen Pettit, 293569

ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE

EHA Library, Giulio Cavalli, 293567

PHENFORMIN INCREASES THE FREQUENCIES OF LSK, MULTIPOTENT PROGENITOR, AND MYELOID PROGENITOR IN JAK2V617F MURINE MODEL OF MYELOPROLIFERATIVE NEOPLASM

EHA Library, Antonio Bruno Alves-Silva, 293564

MOLECULAR CHARACTERISATION OF THE DER(6)T(1;6) IN MYELOID NEOPLASMS

EHA Library, Sophie Laird, 293563

FREQUENCY OF BCR-ABL1, JAK2V617F, MPLW515L/K AND CALR TYPE 1,2 MUTATIONS CO-OCCURENCE IN CML PATIENTS UNDERGOING TKI THERAPY AND ITS POSSIBLE PROGNOSTIC VALUE

EHA Library, Adhamjon Abdullaev, 293562

EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS

EHA Library, Ciro Rinaldi, 293560

HOMOZYGOUS CALRETICULIN MUTATIONS AFFECT CHAPERONE FUNCTION AND PERTURB THE GLYCOPROTEOME

EHA Library, Patrick Schürch, 293557

NECROPTOTIC SIGNALING IS ENHANCED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH MYELOFIBROSIS (MF)

EHA Library, Veronika Dill, 293556

CLONAL HETEROGENEITY AND EVOLUTION OF MPN REVEALED BY SINGLE-CELL RNA/DNA SEQUENCING

EHA Library, Xingxing Qi, 293549

IN SYSTEMIC MASOCYTOSIS, MIDOSTAURIN TARGETS BOTH KIT AND AURORA KINASE A REVERTING H3K36ME3 DEFICIENCY AND SYNERGIZES WITH NILOTINIB AND DASATINIB

EHA Library, Manuela Mancini, 293548

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY

EHA Library, Moshe Talpaz, 293580

AVAPRITINIB INDUCES RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), REGARDLESS OF PRIOR MIDOSTAURIN THERAPY

EHA Library, Jason Gotlib, 293568

CLINICAL SIGNIFICANCE OF MPL MUTATIONS IN ESSENTIAL THROMBOCYTEMIA PATIENTS: RISK ASSESMENT OF MYELOFIBROTIC TRANSFORMATION.

EHA Library, Rocío García-Serra, 293566

CLINICAL AND BIOLOGICAL FEATURES DISTINGUISH MYELOID DISEASES FROM MYELOID DISORDERS ASSOCIATED WITH AUTOIMMUNE DISEASES.

EHA Library, Sara Galimberti, 293565

REWIRED CELL ENERGY METABOLISM IN A NOVEL KRAS-MUTATED HISTIOCYTOSIS CHARACTERIZED BY SEVERE SYNOVITIS

EHA Library, Giulio Cavalli, 293561

THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF THE IMMUNESUPPRESSIVE MICROENVIRONMENT IN MYELOFIBROSIS AND MAY PREDICT RESPONSE TO RUXOLITINIB

EHA Library, Alessandra Romano, 293558

NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES TO IDENTIFY POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME

EHA Library, Martina Barone, 293555

A NOVEL IN VITRO PLATFORM FOR THE PRIORITISATION AND VALIDATION OF INHIBITORS OF BONE MARROW FIBROSIS USING HUMAN BONE MARROW (BM) STROMAL CELLS

EHA Library, Michela Colombo, 293554

HLA CLASS I GENOTYPE SHAPES JAK2 V617F DRIVEN LEUKEMOGENESIS

EHA Library, Velizar Shivarov, 293553

IL-1RA LEVEL IN THE SERUM IS STRONGLY CORRELATED WITH THE JAK2V617F ALLELE BURDEN, MYELOFIBROSIS, SPLENOMEGALY AND SLAMF7HIGH CD16− MONOCYTES IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Takaaki Maekawa, 293552

SETD2 PROTEIN LEVELS ARE A NOVEL PREDICTOR OF OVERALL SURVIVAL IN SYSTEMIC MASTOCYTOSIS

EHA Library, Michela Rondoni, 293550

TELOMERASE ACTIVITY, TELOMERE LENGTH AND HTERT EXPRESSION CORRELATE WITH CLINICAL OUTCOMES IN HIGHER-RISK MYELOFIBROSIS (MF) RELAPSED/REFRACTORY (R/R) TO JANUS KINASE INHIBITOR TREATED WITH IMETELSTAT

EHA Library, John Mascarenhas, 293587

NAVITOCLAX IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS: A PHASE 2 STUDY

EHA Library, Claire Harrison, 293570

RESULTS FROM PIONEER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF AVAPRITINIB IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS

EHA Library, Cem Akin, 293571

CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS 'ADD-ON' TO RUXOLITINIB (RUX), IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY

EHA Library, Srdan Verstovsek, 293572

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: UPDATE FROM MANIFEST PHASE 2 STUDY

EHA Library, John Mascarenhas, 293573

ROPEGINTERFERON ALPHA-2B IS EFFICACIOUS AND REDUCES VARIANT TET2 ALLELE BURDEN IN PATIENTS WITH POLYCYTHAEMIA VERA AND TET2 MUTATION: GENETIC ANALYSIS OF PHASE III PROUD-PV/CONTINUATION-PV STUDIES

EHA Library, Robert Kralovics, 293574

CO-MUTATIONS AND NON-CANONICAL DRIVER MUTATIONS IDENTIFIED BY NEXT GENERATION SEQUENCING IN MYELOPROLIFERATIVE NEOPLASMS REVEAL SIGNIFICANT OPPORTUNITIES FOR IMPROVED DIAGNOSTIC PRACTICE

EHA Library, Ella Thompson, 293576

CLINICIAL, MORPHOLOGICAL AND GENETIC EVIDENCE FOR TWO INDEPENDENT DISEASES IN PATIENTS CONCURRENTLY POSITIVE FOR JAK2 V617F AND KIT D816V

EHA Library, Juliana Schwaab, 293577

INTERIM ANALYSIS OF A PHASE II TRIAL (HOVON-134) IN MYELOFIBROSIS PATIENTS (PRIMARY, POST-ET OR POST PV-MF) TREATED WITH THE JAK2 INHIBITOR PACRITINIB BEFORE RIC ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Peter te Boekhorst, 293578

CHRONIC NEUTROPHILIC LEUKEMIA AND ATYPICAL CHRONIC MYELOID LEUKEMIA ARE HIGLY OVERLAPPING DISORDERS. RESULTS FROM AN INTERNATIONAL BRITISH-SPANISH STUDY

EHA Library, Gonzalo Carreno Gomez-Tarragona, 293579

MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE: CLINICOPATHOLOGICAL CHARACTERISATION AND OUTCOME ANALYSIS

EHA Library, Paul Deschamps, 293581

PHENOTYPIC DIFFERENCES AND PROGNOSTIC IMPACT OF SIGNALING MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Evandro Bezerra, 293582

LONG-TERM SAFETY OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Animesh Pardanani, 293585

EXPLOITING THE CD47-SIRPΑ MACROPHAGE CHECKPOINT TO CONTROL POLYCYTHEMIA VERA

EHA Library, Veronika Lysenko, 293547